Clinician

A jar promise for the face is not what this paper measured.

Last updated 2026-09-18

What to say and what to ask. This page does not diagnose, prescribe, or sell a cream.

This page does not diagnose or prescribe. It is a prompt sheet you can take to a clinician you already trust. MenoDerm cannot book an appointment and does not recommend starting, stopping, or changing HRT or any other treatment.

Say

Bring the ordinary details. They matter more than a paper.

• “I am reading a topical estradiol site-contrast study, not an over-the-counter anti-aging jar trial.”
• “The claim I care about is: short-term topical estradiol raised collagen markers on sun-protected hip skin, but not on photoaged face or forearm in that study, so a jar promise for the face is not what this paper measured.”
• “Site contrast is the point. About 40 postmenopausal women and 30 men. Mean age about 75. Topical estradiol for 2 weeks.”
• “I also saw Haapasaari 1997: open, early post-menopause, about 43 women, about 1 year (about 12 months) of systemic estrogen alone or with progestin, no significant effect on the collagen parameters studied.”
• “I am reading Affinito 1999 (Maturitas): laparotomy-skin biopsies performed during laparotomic operation, not a face jar trial.”
• “The claim I care about from Affinito is: postmenopausal women had lower type I and type III collagen percentages than premenopausal women, with an inverse link to years since menopause, on laparotomy skin.”
• “n=32 (14 pre / 18 post); mean age 48.78±9.86; range 28-68; immunohistochemistry and computerised image analysis.”
• “Authors suggest an estrogen-related decrease. I am treating that as medical information, not a prescription from a content site.”
• “I already know the brakes on this moment (Rittié site contrast; Haapasaari open null year). I am not asking MenoDerm to start, stop, or change HRT, and I am not asking for a cream (there is none).”
• “I am reading Brincat 1985 and 1987 (BJOG): thigh / non-face skin structure under estrogen status, not a face jar trial.”
• “The claim I care about is: in untreated women, thigh skin collagen fell with years since menopause, and in the earlier study skin collagen declined with menopausal age more than chronological age; implant-treated groups did not show the same decline and had greater skin collagen and thickness.”
• “1987: 69 untreated and 37 on oestradiol and testosterone implants for 2 to 10 years; thigh collagen measured.”
• “1985: sex hormone implants versus untreated; treated had greater collagen and thickness; untreated collagen tracked menopausal age, not chronological age. Exact n and biopsy site for 1985 are not in the abstract I am using.”
• “Implant regimens here are medical information only. I am not asking MenoDerm to start, stop, or change HRT, and I am not asking for a cream (there is none). Chinese wall versus any retail brand.”
• “I already know the LIVE brakes on this moment (Rittié site contrast; Haapasaari open null year) and the Affinito body-wall histology complement.”
• Where it happens, what you already use, and any prescribed creams or hormones you are already on. Do not change them from this site.

Ask

• These pages cite Rittié 2008 (topical estradiol for 2 weeks; about 40 postmenopausal women and 30 men; mean age about 75; hip versus photoaged face and forearm). How should I read hip collagen-marker induction with a face and forearm null when counseling about anti-aging claims?
• Topical estradiol on these pages is information only. How do you separate that from over-the-counter jar language patients bring in?
• Haapasaari 1997 is open and non-randomized (early post-menopause; about 43 women; about 1 year, about 12 months, of systemic estrogen alone or with progestin; null on collagen parameters studied). How do you place that null next to positive thickness or collagen literature without overclaiming either way?
• These pages cite Affinito 1999 (Maturitas; n=32; 14 pre / 18 post; mean age 48.78±9.86; range 28-68; laparotomy-skin biopsies during laparotomic operation; type I/III by immunohistochemistry and computerised image analysis; inverse link to years since menopause). How should I place laparotomy-skin histology next to facial photoaging counseling?
• The abstract says an inverse correlation with years of postmenopause and reports r = 0.76 / 0.73 / 0.73 (P<0.01), pairing the word inverse with positive r. How do you read that for patients without overclaiming a face endpoint?
• Authors call the decrease estrogen-related. How do you separate that suggestion from OTC jar language and from HRT start/stop decisions?
• How do you put Affinito next to the Rittié hip-versus-face brake and the Haapasaari null year without overclaiming either way?
• These pages cite Brincat 1987 (BJOG; thigh collagen; 69 untreated / 37 oestradiol and testosterone implants for 2 to 10 years; untreated decline with years since menopause) and Brincat 1985 (implant-treated greater collagen and thickness; untreated decline with menopausal age not chronological age). How should I place implant-era thigh structure next to facial photoaging counseling?
• How do you separate “structure changed with estrogen status” from OTC jar language patients bring in, and from HRT start/stop decisions?
• How do you put Brincat next to the LIVE Rittié hip-versus-face brake, the Haapasaari null year, and Affinito laparotomy histology without overclaiming either way?
• I want help matching jar claims and exam findings, not a prescription from a content site.

Maheux 1994 + Dunn 1997 (clinician twin)

This twin is clinician-primary. It does not replace the LIVE brakes above. Dunn does not sit on cream-sits.

Say

• “I am reading Maheux 1994 (AJOG) and Dunn 1997 (Arch Dermatol): a systemic conjugated-estrogens RCT on body-site thickness, plus a large NHANES association study. Not a face jar trial and not a cream-sits card.”
• “The claim I care about is: in a 12-month RCT, oral conjugated estrogens increased ultrasound skin thickness and dermal thickness at the right great trochanter versus placebo. Separately, among 3875 postmenopausal women, estrogen use was associated with lower odds of senile dry skin (OR 0.76; 0.60-0.97) and wrinkling (OR 0.68; 0.52-0.89) on dermatologist exam, and was not associated with atrophy. That is association, not a prescription trial, and not a cream-sits claim.”
• “Maheux: 60 women; double-blind conjugated estrogens versus placebo for 12 months; right great trochanter (body site, not face); ultrasound skin thickness up (p < 0.01) and dermis up on biopsy (p < 0.05). Dose in milligrams is not in the abstract I am using. Do not invent a thickness percent.”
• “Dunn: cross-sectional NHANES I; n=3875 postmenopausal women; self-report noncontraceptive estrogen; surface exam only; not TEWL or ceramides. Senile dry skin OR 0.76 (0.60-0.97); wrinkling OR 0.68 (0.52-0.89); smoking-adjusted wrinkling OR 0.67 (0.44-1.01; CI includes 1.0). Not associated with atrophy. Association, not a prescription trial. Design has been critiqued.”
• “Systemic hormones and estrogen-use associations here are medical information only. I am not asking MenoDerm to start, stop, or change HRT, and I am not asking for a cream (there is none).”
• “I already know the LIVE brakes on this moment (Rittié site contrast; Haapasaari open null year) and the Affinito / Brincat structure neighbors.”

Ask

• These pages cite Maheux 1994 (AJOG; n=60; 12-month conjugated estrogens versus placebo; right great trochanter; ultrasound skin thickness up p < 0.01 and dermal thickness up p < 0.05 versus placebo) and Dunn 1997 (Arch Dermatol; cross-sectional NHANES I; n=3875; OR 0.76 dry skin / 0.68 wrinkling; smoking-adjusted wrinkling 0.67, CI includes 1.0; not atrophy). How should I place a systemic body-site RCT and a cross-sectional association next to facial photoaging counseling?
• How do you separate “ask about whole-person hormones” from OTC jar language patients bring in, and from HRT start/stop decisions?
• How do you put Maheux next to the LIVE Haapasaari null year without overclaiming either way, and Dunn next to dryness talk without turning it into a cream-sits or TEWL claim?
• I want help matching jar claims and exam findings, not a prescription from a content site.

Must not

This copy must not prescribe a brand, sell a cream, start or stop HRT, recommend topical estrogen for facial anti-aging, claim OTC creams restore collagen I/III or thickness or prevent wrinkles, diagnose from this copy, place Dunn on cream-sits, or use SisLuna / Payot product language.

It must not claim OTC creams restore collagen or use SisLuna / Payot product language. Implant regimens are medical information only.

Go sooner

Contact a clinician promptly (same day or urgent care if that is what is available) for a spreading rash, pus, fever, painful cracking, bleeding, or new involvement of the eyes, genitals, or large areas of skin. Seek emergency help now for trouble breathing, swelling of the lips, tongue, or throat, faintness, severe eye pain or vision changes, blistering, or rapidly worsening skin. If you think a prescribed cream or hormone therapy is involved, contact the prescriber promptly; do not change it from this site.

Source rules